Key Insights

Highlights

Treatment Research

1 treatments under study, led by Atsn201

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05878860Phase 3Recruiting

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Showing all 1 trials

Research Network

Common Treatments

  • Atsn2011

Active Sponsors

  • Atsena Therapeutics Inc.1

Related Conditions

  • Xlinked Retinoschisis1

Activity Timeline